PPARG and Insulin resistance: Treatment with an AT1R blocker (irbesartan, losartan, telmisartan) decreases WAT release of inflammatory cytokines (leptin, IL-6, and IL-17) and miRNA associated with ER stress (miR-708-5p, miR-143-3p) and improves adipogenesis (partial PPARγ agonist effect), insulin resistance, markers of adipocyte senescence, mitochondrial ROS, and secretion of anti-inflammatory adipokines such as adiponectin [252,254].